Crinetics Pharmaceuticals Inc (CRNX)

1ightning® Options Trade Alert (Actionable) | Buy $CRNX Dec 19 $45 Call | Enter: $2.51 Exit: $3.60 | Profit: 43.69% ROI | https://1ightning.com

$CRNX $QQQ One to keep an eye / alert on......Right at an important technical area of interest:

$CRNX $XPH $QQQ Still trying, would like to see upward price conviction with a break/close above:

$CRNX 😎 was nice PDUFA run

$CRNX $XPH $QQQ Maybe not going to happen today at least:

My (very simple) strategy with Playbook is to make a list of high-quality setups as I find them Then prioritize based on which are most actionable or r/r too attractive to pass up $CRNX $DERM Planning your purchases ahead of time is a great way to combat emotions, FOMO & greed

JonesTrading⬆️ $RZLT's PT to $14 from $12 and reiterated at a Buy rating. $ZLDPF $CRNX $AMLX Here's what JonesTrading had to say in its note:

$CRNX $XPH $QQQ CRNX / Daily - Price consolidating, right at a common 50% fib retracement (of the Nov '24 - Apr '25 sell off), with some momentum that's been building underneath. Potentially, would watch - Both a confirmation/breakout/close above the 50% fib and consolidation/flag pattern - and especially with any conviction should that occur in the near term:

Citizens updates rating for Crinetics Pharmaceuticals ( $CRNX ) to Market Outperform, target set at 143 → 108.

$CRNX Might be back if we see irrational gap fill to 35.

$CRNX "Heads up alert! Only one day until Upcoming earnings on Thursday, 11/6/2025 for $CRNX Bullish (8.1) Crinetics Pharmaceuticals, Inc. (CRNX) continues to demonstrate significant momentum in the biotech sector, particularly following the recent FDA approval of its drug Palsonify for the treatment of acromegaly. This milestone not only underscores the company's innovative capabilities but also enhances its market position significantly. The stock has seen a notable increase of approximately 35% in value, reflecting strong investor confidence and a positive reception from the market. Financially, Crinetics is positioned with a market capitalization around $4.X.3 billion, indicating robust growth potential. Analysts are optimistic, with Cantor Fitzgerald maintaining a Buy rating and setting a price target of $90, while JMP Securities has raised their target to $143, suggesting over 200% upside from current levels. The company's P/E ratio remains competitive within the industry, and its earnings per share (EPS) growth is projected to be strong as Palsonify enters the market. Revenue forecasts are promising, driven by the anticipated uptake of Palsonify, especially as it addresses a significant unmet need in the treatment of acromegaly. Comparatively, Crinetics appears to be outperforming its industry peers, with analysts highlighting its unique product offerings and strategic positioning in the neuroendocrine tumor space. Looking ahead, Crinetics is set to report its third-quarter financial results on November 6, 2025. Analysts are closely watching this event, as it will provide further insights into the company's financial health and operational progress post-FDA approval. Historical performance indicates a consistent trajectory of growth, and consensus estimates suggest that earnings will reflect a positive response to the recent product launch. Investors are likely to assess management's commentary on Palsonify's market penetration and any updates on pipeline projects during the earnings call, which could further influence stock performance. Overall, the healthcare sector, particularly the biotech segment, has shown resilience and growth, with Crinetics at the forefront of this trend. The NYSE Health Care Index has experienced gains, reflecting broader investor optimism in innovative healthcare solutions. As CRNX continues to develop its product pipeline and capitalize on recent approvals, it stands well-positioned to leverage market opportunities and drive shareholder value. - Funds were net buyers of $CRNX during the previous reporting quarter. - Funds with large holdings in $CRNX include: - Driehaus Capital, MV: $184MM. Fund Rank: 58% - Farallon Capital Management LLC, MV: $134MM. Fund Rank: 70% www.faralloncapital.com - EcoR1 Capital LLC, MV: $123MM. Fund Rank: 56% ecor1cap.com - Paradigm Biocap, MV: $67MM. Fund Rank: 62% - Point72 Asset Management LP, MV: $57MM. Fund Rank: 91% www.point72.com - Last 10 days performance: 8% - Last 30 days performance: 5% - Last 90 days performance: 56% Some of the latest news articles: - Title: Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting Publication Date: 10/23/2025 12:00:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/crinetics-highlight-neuroendocrine-tumor-research-120000542.html?.tsrc=rss - Title: Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Publication Date: 10/10/2025 8:41:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/crinetics-pharmaceuticals-announces-october-2025-204100997.html?.tsrc=rss - Title: Cantor Fitzgerald Maintains a Buy Rating on Crinetics Pharmaceuticals (CRNX) Publication Date: 10/7/2025 5:04:45 PM, Source: yahoo URL: https://finance.yahoo.com/news/cantor-fitzgerald-maintains-buy-rating-170445702.html?.tsrc=rss - Title: A Look at Crinetics Pharmaceuticals's Valuation Following FDA Approval of PALSONIFY for Acromegaly Publication Date: 10/7/2025 2:26:35 PM, Source: yahoo URL: https://finance.yahoo.com/news/look-crinetics-pharmaceuticalss-valuation-following-142635281.html?.tsrc=rss Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."

$CRNX Headed into Q3 call Thu 11/6, 1:30pm PT. I’m listening for early paltusotine launch color (Q4 patient starts, prescriber uptake, payer coverage/GTN) and any WAC confirmation, plus cash/runway as launch + Ph3 ramp, pipeline timing (carcinoid Ph3, atumelnant), and ex-US (EU MAA/Japan).

$CRNX we shall see.

$INVA This is next, we hit $CRNX and $GKOS 25 % plus. Do your DD. PDUFA Date: Dec 15, 2025 Zoliflodacin — Oral antibiotic for gonorrhea FDA Likelihood: Very high (Priority Review, strong Phase 3, urgent CDC priority). Market Impact: Medium–large public health value, smaller direct commercial revenue. U.S. gonorrhea cases ~700k/year (CDC). New oral option = government/NGO contracts, global demand, less private pricing power. Potential: Blockbuster public health win, but sales may be constrained by stewardship and generic pricing.

$CRNX With Paltusotine already approved for Acromegaly, I think approval for carcinoid, likely to follow. Atumelnant up next for Hyperplasia

$CRNX nice movement. if we can break through $46, it’s smooth sailing above

$CRNX Key highlights include a preliminary, investigator-assessed one-year progression-free survival (PFS) rate of 74% from an open-label Phase 2 study of paltusotine for carcinoid syndrome and poster details on the randomized Phase 3 CAREFNDR study of paltusotine and the first-in-human study of nonpeptide drug conjugate CRN09682

$CRNX did something happen?

$CRNX Looking to get in here but why has this faltered since approval last month, anyone know? Was at $45 and i was expecting it to be over $50 by now.